Related Experiment Video
Updated: Jul 5, 2026

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
Use of sirolimus in IPEX and IPEX-like children
Pierre L Yong1, Pierre Russo, Kathleen E Sullivan
1Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. pyong@mail.med.upenn.edu
Introduction:
IPEX (immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome), a rare inflammatory disease caused by mutations of Foxp3, destroys the immunoregulatory environment of affected male infants. Data on optimal therapy are limited.
Methods:
We reviewed the effect of sirolimus use in our cohort of IPEX and IPEX-like patients (n = 7).
Results And Discussion:
Our patients exhibited features of enteropathy and recurrent infections with bacterial and viral pathogens. Before initiating sirolimus, six patients were treated with corticosteroids. Several also received other immunosuppressive agents. After starting sirolimus, six patients had improvement in diarrhea, and two were able to decrease corticosteroid dosages. Several also had significantly decreased number of infections after treatment. Of the three patients with post-treatment duodenal biopsies, two showed improvement in villous architecture. No significant adverse events occurred. Our experience suggests that sirolimus is a clinically effective and safe therapeutic option in IPEX and IPEX-like patients.
Related Concept Videos
iPS Cell Differentiation
EPS and iPS Cells in Disease Research
Pharmacokinetics in Pediatric Patients: Drug Excretion
Clinical Applications of Epidermal Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...
